DK1432450T3 - Terapeutisk anvendelige triethylenglycol-cholesteryl-oliconucleotider - Google Patents

Terapeutisk anvendelige triethylenglycol-cholesteryl-oliconucleotider

Info

Publication number
DK1432450T3
DK1432450T3 DK02775055T DK02775055T DK1432450T3 DK 1432450 T3 DK1432450 T3 DK 1432450T3 DK 02775055 T DK02775055 T DK 02775055T DK 02775055 T DK02775055 T DK 02775055T DK 1432450 T3 DK1432450 T3 DK 1432450T3
Authority
DK
Denmark
Prior art keywords
seq
induction
composition
cholesteryl
oliconucleotides
Prior art date
Application number
DK02775055T
Other languages
Danish (da)
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Andrea Cristina Herrera-Gayol
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DK1432450T3 publication Critical patent/DK1432450T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK02775055T 2001-10-03 2002-10-03 Terapeutisk anvendelige triethylenglycol-cholesteryl-oliconucleotider DK1432450T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32688401P 2001-10-03 2001-10-03

Publications (1)

Publication Number Publication Date
DK1432450T3 true DK1432450T3 (da) 2006-05-15

Family

ID=23274136

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02775055T DK1432450T3 (da) 2001-10-03 2002-10-03 Terapeutisk anvendelige triethylenglycol-cholesteryl-oliconucleotider

Country Status (16)

Country Link
US (1) US7635686B2 (xx)
EP (1) EP1432450B1 (xx)
JP (1) JP4405259B2 (xx)
KR (1) KR100971571B1 (xx)
CN (1) CN100352510C (xx)
AT (1) ATE314096T1 (xx)
AU (1) AU2002341264B2 (xx)
CA (1) CA2462425A1 (xx)
DE (1) DE60208400T2 (xx)
DK (1) DK1432450T3 (xx)
ES (1) ES2250713T3 (xx)
HK (1) HK1067308A1 (xx)
IL (2) IL161181A0 (xx)
MX (1) MXPA04002530A (xx)
PT (1) PT1432450E (xx)
WO (1) WO2003028764A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785212B2 (en) * 1999-12-13 2006-11-09 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
KR101092043B1 (ko) * 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
US20090054366A1 (en) * 2007-06-15 2009-02-26 Reliance Life Sciences Pvt. Ltd. RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
EP0731636B1 (en) * 1993-11-30 2006-01-11 Tanox, Inc. Cdn apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
WO1997014440A1 (en) 1995-10-19 1997-04-24 Johnson & Johnson Interventional Systems Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
US5958780A (en) * 1997-06-30 1999-09-28 Boston Advanced Technologies, Inc. Method for marking and identifying liquids
US6465175B2 (en) 1997-09-04 2002-10-15 Bayer Corporation Oligonucleotide probes bearing quenchable fluorescent labels, and methods of use thereof
EP0979869A1 (en) * 1998-08-07 2000-02-16 Hoechst Marion Roussel Deutschland GmbH Short oligonucleotides for the inhibition of VEGF expression
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
AU785212B2 (en) * 1999-12-13 2006-11-09 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
CN101113160A (zh) * 2001-05-16 2008-01-30 米珍尼克斯公司 基于核酸的化合物及其使用方法

Also Published As

Publication number Publication date
ATE314096T1 (de) 2006-01-15
KR20040068114A (ko) 2004-07-30
CN1599627A (zh) 2005-03-23
DE60208400T2 (de) 2006-07-06
DE60208400D1 (de) 2006-02-02
WO2003028764A1 (en) 2003-04-10
PT1432450E (pt) 2006-05-31
US7635686B2 (en) 2009-12-22
IL161181A (en) 2010-06-30
AU2002341264B2 (en) 2007-07-12
CA2462425A1 (en) 2003-04-10
IL161181A0 (en) 2004-08-31
EP1432450A1 (en) 2004-06-30
KR100971571B1 (ko) 2010-07-20
EP1432450B1 (en) 2005-12-28
JP2005509607A (ja) 2005-04-14
CN100352510C (zh) 2007-12-05
MXPA04002530A (es) 2004-05-31
JP4405259B2 (ja) 2010-01-27
ES2250713T3 (es) 2006-04-16
US20030125290A1 (en) 2003-07-03
HK1067308A1 (en) 2005-04-08

Similar Documents

Publication Publication Date Title
ES2148486T3 (es) Intermediarios de cloropirimidina.
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
WO2002028904A3 (en) Human anti-cd40 antibodies
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
ATE224386T1 (de) Neue in 6-position substituierte phenanthridine
EP0954334A4 (en) Use of macrophage migration inhibitory factor antagonists for cancer therapy
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DK1001761T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsunderskudslidelser
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
HK1033910A1 (en) Use of erythropoietin in the treatment of multiple myeloma
DK1432450T3 (da) Terapeutisk anvendelige triethylenglycol-cholesteryl-oliconucleotider
PL340467A1 (en) Application of mithrazapin in treating apnoea dissomnia
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
UY26426A1 (es) Nuevos compuestos
ATE427746T1 (de) 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
TR200200278T2 (tr) Kalsilitik bileşimler
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
BR9912153A (pt) Piperazinonas substituìdas e uso terapêuticos das mesmas
MX9700113A (es) Amido-quinoxalindionas novedosas, su preparacion y uso.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DK1051404T3 (da) Substituerede phenyluraciler med herbicid virkning
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine